Labcorp Holdings Inc. hosted its 2026 Investor Day on September 10, 2026, reaffirming full-year 2026 guidance and providing a long-term financial outlook through 2029. The company expects compound annual revenue growth of 5% to 8% and adjusted EPS growth of 8.5% to 11.5%. For 2026, Labcorp projects enterprise revenue between $14.71 billion and $14.83 billion, with adjusted earnings per share ranging from $18.10 to $18.55. The firm outlined strategic priorities focused on specialty testing in oncology, neurology, autoimmune diseases, and women’s health, alongside investments in artificial intelligence and robotics. Labcorp operates as a global leader of innovative and comprehensive laboratory services.

On August 11, 2026, Megan D. Bailey resigned as Executive Vice President and President of Central Laboratories and International, effective September 4, 2026. Brian J. Caveney, M.D., currently Executive Vice President and President of Early Development Research Laboratories and Chief Medical and Scientific Officer, will assume the role of Executive Vice President and President of Biopharma Laboratory Services and Chief Medical and Scientific Officer on September 1, 2026, overseeing both Early Development Research and Central Laboratories businesses. Labcorp Holdings Inc. operates in the healthcare industry, providing clinical laboratory services.

Labcorp Holdings Inc. reported second quarter 2026 results with revenue of $3.73 billion, a 5.8% increase year-over-year, and diluted EPS of $3.64, up 28.5%. The company raised its full-year guidance, setting enterprise revenue growth at 5.4% to 6.3% and adjusted EPS between $18.10 and $18.55. Labcorp announced a $1.0 billion increase in share repurchase authorization, bringing the remaining total to $1.4 billion. Additionally, the Board approved a quarterly cash dividend of $0.72 per share, payable on September 11, 2026, to stockholders of record as of August 28, 2026. The company operates in the healthcare diagnostics and clinical laboratory services industry.

Labcorp Holdings Inc. (NYSE: LH) declared a cash dividend of $0.72 per share of common stock, payable on September 11, 2026, to stockholders of record as of August 28, 2026. Labcorp Holdings Inc. is a global provider of laboratory services.